US drug maker Pfizer has asked Japan's health ministry to approve the use of its updated coronavirus vaccine for children aged five to 11. The firm says the vaccine is effective against the prevailing Omicron BA.5 subvariant.
Pfizer said it filed the request on Thursday. The so-called bivalent vaccine targets the BA.4 and BA.5 subvariants, as well as earlier strains.
Messenger RNA-based vaccines enable the human body to create spike proteins and build up an immune response.
The vaccine for the BA.5 subvariant is currently available for those aged 12 or older in Japan.
On Wednesday, the US Centers for Disease Control and Prevention approved the use of the firm's updated coronavirus booster shots for children as young as five.
Pfizer said it filed the request on Thursday. The so-called bivalent vaccine targets the BA.4 and BA.5 subvariants, as well as earlier strains.
Messenger RNA-based vaccines enable the human body to create spike proteins and build up an immune response.
The vaccine for the BA.5 subvariant is currently available for those aged 12 or older in Japan.
On Wednesday, the US Centers for Disease Control and Prevention approved the use of the firm's updated coronavirus booster shots for children as young as five.
Similar Readings (5 items)
Japan to provide Omicron vaccines to public starting October
Japan to roll out Moderna vaccine for BA.5, adding to Pfizer's vaccine
Japan approves coronavirus vaccine aimed at Omicron
Japan approves 5 coronavirus vaccines for inoculation campaign
Japanese health ministry panel endorses use of Daiichi Sankyo COVID shot
Summary
Pfizer has submitted a request to Japan's health ministry for approval of its updated COVID-19 vaccine for children aged 5 to 11. The vaccine targets Omicron BA.4 and BA.5 subvariants, as well as earlier strains. Currently, the vaccine for the BA.5 subvariant is available in Japan for those 12 or
Statistics
120
Words1
Read CountDetails
ID: 918e114d-85d3-4972-94b3-aed4455bf4f0
Category ID: nhk
URL: https://www3.nhk.or.jp/nhkworld/en/news/20221013_22/
Date: Oct. 13, 2022
Created: 2022/10/13 20:33
Updated: 2025/12/09 12:46
Last Read: 2022/10/14 13:09